This phase III trial demonstrates that #ARX788 significantly improves #ProgressionFreeSurvival over lapatinib plus capecitabine in #HER2-positive advanced #BreastCancer, showing strong efficacy and manageable ocular and #PulmonaryToxicity.

#OpenAccess #STTT: doi.org/10.1038/s413...